U.S. commercialization partnership and Phase III trial and FDA review for CAP-1002

A discrete development theme based on the U.S. commercialization partnership with Capricor Therapeutics, covering preparation for the Phase III trial of CAP-1002, submission of materials to the FDA and resumption of FDA review after the CRL, through the setting of a PDUFA date.